الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 90 |  |  |
| | | from | 90 | | |
Abstract
Systemic immune suppression is often seen in cancer patients and is
thought to contribute to patient morbidity via tumor-mediated immune
evasion.
Indeed, patients with compromised immune systems are at increased
risk of developing non-Hodgkin lymphoma (NHL).
Non-Hodgkin’s lymphomas represent malignant proliferations of the
immune system cells which start and affect predominantly the lymphoid
organs, but may have as onset or may involve during their evolution any
organ or tissue where these cells are.
Myeloid -derived suppressor cells (MDSCs) are a heterogeneous
population of immature myeloid cells at different stages of maturation that
play a role in cancer tolerance and function as an immune-suppressive cell
subpopulation. They utilize different mechanisms to block both innate and
adaptive arms of anti-tumour immunity, mostly through inhibition of T cell
activation and expansion.
Two major classes have been recognized Granulocytic MDSCs (GMDSCs)
and monocytic MDSCs (M-MDSCs).M-MDSCs express
CD14with minimal or no HLDR expression.
The aim of this study is to detect CD14+HLA-DRlow/-immunosuppressive
monocytes in NHL patients as major contributor to systemic
immunosuppression which could have an effect on disease aggressiveness
and treatment strategy.
This study was carried out on 42 NHL patients, 14 males and 28 females,
with age range of 33 to 71 years old attending the Oncology department,
Minoufiya University hospitals. Of the 42 NHL cases 16 were relapsed or
refractory and 26 were newly diagnosed cases. Tweenty age and gender
matched individuals were selected as a control .
We analysed CD14+ HLA DRlow/- monocytes by flowcytometry and
arginase 1 enzyme analysis by ELISA.
On statistical analysis of the collected data there was increased ratio of
CD14+ HLA DRlow/- monocytes in patients with higher stage disease ,more
aggressive pathology and also with refractory and relapsed disease with the
agreement of arginase-1 results with CD14+ HLA DRlow/- monocytes.